However, a murine breast cancer model treated with a DCV containing IDO-silenced DCs demonstrated enhanced CD8+ T-cell activity, reduced Treg infiltrates and decreased tumour size compared to antigen-loaded DC-based vaccine without concomitant IDO silencing [361]. This evidence concerns the gene IDO1 and breast carcinoma.